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Abstract
The supply of new diagnostics and treatments is insufficient to
keep up with the increase in antimicrobial resistance (AMR) and
multidrug resistance (MDR) as older medicines are used more
widely and microbes develop resistance to them. At the same time,
significant quantities of antibiotics are used on patients and animals
that do not need them, while others who do need them lack access.
Effective responses to AMR/MDR require effort by both the public and
private sectors to develop and disseminate new diagnostics, vaccines
and treatments on a global scale, as well as to adapt them to local needs.
This calls for good governance to identify priorities, raise awareness and
ensure effective stewardship at global, regional and national levels to
minimize the development of resistance. Failure to act appropriately in
one country will adversely impact all countries as resistance travels fast.
Based on a review of recent literature, this WIPO Global
Challenges Report includes a broad overview of current
approaches and consortia designed to meet the challenge of
research and development (R&D) investment for new treatments.
It also examines patent applications by both the public and
the private sectors as an indicator of innovative activity.
This report finds that there is a need to address the unique market
challenges and specific uncertainties associated with the development
of new diagnostics and treatments, where current approaches are not
optimal. An effective global framework that achieves the necessary
political support while ensuring effective local implementation is
crucial. There is an opportunity to complement this work by formulating
mechanisms that drive innovation for results to incentivize success,
while feeding expertise and experience into stewardship and access
efforts. Intellectual property (IP) could be used in a constructive
manner as one element in any reward or prize system for AMR/MDR
R&D – both in terms of providing an incentive and governance.
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1. Introduction
In 1928 a piece of mold contaminated a petri dish, killing bacteria under examination. This led Alexander
Fleming to one of the greatest discoveries in modern medicine, and within 12 years Fleming and others
turned this finding into a wonderdrug that could cure patients with bacterial infections. Common – yet
frequently deadly – illnesses such as pneumonia and tuberculosis (TB) could be treated effectively.
But bacteria and other pathogens are also great innovators and are adept at developing resistance
to antibiotic medicines. Overuse, misuse, and/or lack of patient adherence to complete the course
have led to ever-increasing levels of resistance to antibiotic treatment. Resistance has become particularly problematic in recent years because the pace at which novel antibiotics are being discovered
has slowed drastically while antibiotic use continues to rise. The routine addition of antibiotics in food
animal production significantly increases the probably of resistance.1 The great strides made over the
past few decades to effectively treat HIV/AIDS, TB and malaria could be reversed, leading to these
and other diseases spiralling out of control. Figure 1 shows the impact of antibiotics on public health. It
compares the 10 leading causes of death as a percentage of all deaths in the United States of America
(USA) in 1900 and 1997. Major and minor surgery could once again result in fatal infections and many
treatments that have become commonplace would not be possible without high risk. AMR/MDR therefore threatens many of the most important medical advances made this century. But the impact goes
far beyond health systems. A conservative estimate is that AMR currently accounts for over 700,000
deaths annually, but this could rise to 10 million in 2050 if not effectively addressed.2
This research brief sets out the approaches currently taken at the highest political level, right through
to the practical steps being taken in the fight to overcome the microbes, and tries to identify opportunities for innovation and intellectual property (IP) systems to play an active role in the global effort.

Figure 1:
The impact of the introduction of antibiotics on public health: the 10 leading
causes of death as a percentage of all deaths in the USA in 1900 and 1997

Source: Mitchell L. Cohen, “Changing patterns of infectious disease”, Nature 406, 762-767, August 17, 2000.
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Collignon et al., “World Health Organization ranking of antimicrobials according to their importance in human medicine:
a critical step for developing risk management strategies to control antimicrobial resistance from food animal production”,
Clinical Infectious Diseases, July 20, 2016.

2

Tackling Drug-Resistant Infections Globally: Final Report and Recommendations, Review on Antimicrobial Resistance,
May 2016; the plausibility of these estimations has been questioned by de Kraker, M.E.A., A.J. Stewardson and S. Harbarth,
2016, “Will 10 million people die a year due to antimicrobial resistance by 2050?”, PLoS Med 13(11): e1002184. doi:10.1371/
journal.pmed.1002184; available at https://doi.org/10.1371/journal.pmed.1002184

2. High-level literature
review
Although there has been a dramatic increase in the attention and focus on AMR/MDR over the past five years or so
(leading to a number of high-level political declarations), the
European Union (EU) and the USA had already established
high-level measures to guide the use of antibiotics.
• On June 8, 1999, the Council of the European Union adopted a Resolution on antibiotic resistance entitled A strategy against the microbial threat,3 which was followed by a
Council recommendation on November 15, 2001 on The
prudent use of antimicrobial agents in human medicine.4
• A US and EU Summit in 2009 declared, inter alia, “To
establish a transatlantic task force on urgent antimicrobial resistance issues focused on appropriate therapeutic
use of antimicrobial drugs in the medical and veterinary
communities, prevention of both healthcare and community-associated drug-resistant infections, and strategies for
improving the pipeline of new antimicrobial drugs, which
could be better addressed by intensified cooperation
between us.”5 This led to the creation of the Transatlantic
Task Force on Antimicrobial Resistance (TATFAR),6 which
seeks to address the above mandate. In its 2014 progress
report7 the Task Force highlighted the ongoing work in the
delivery of recommendations under three key themes:
1. appropriate therapeutic use in human and veterinary
medicine
2. prevention of drug-resistant infections
3. strategies for improving the pipeline of new antimicrobial drugs.
• A paper by the Commission of the Organisation for Economic
Co-operation and Development (OECD) lays out the issues
from the perspective of the G7 countries and beyond.8 The
summary includes the themes as identified by TATFAR but
makes further recommendations for policymakers:
1. Strengthening existing surveillance and monitoring
systems and improving statistics on the consumption
of antimicrobials.
2. The adoption of a globally agreed set of measurable
targets related to the incidence of AMR, as well as to
the efficient use of new antibiotics, would provide political impetus to address AMR.

3. Countries should strengthen their ongoing efforts to
facilitate the upscaling of practices of proven effectiveness and efficiency at national level (for example
stewardship programs, educational campaigns).
4. A concerted international approach to foster innovation,
as well as basic research in the antimicrobial sector,
is crucial to lower many barriers that currently hinder
research and development (R&D), and to increase the
productivity of research at the global level.
5. The OECD, with its distinctive cross-sectoral expertise,
is in a unique position to help G7 countries and their
G20 partners tackle AMR. The OECD can provide a
forum where governments can discuss, develop and
coordinate new strategies for prudent antimicrobial use
in human medicine and agriculture. The OECD can also
evaluate the detrimental economic impact caused by
AMR. Finally, it can review and assess the most promising innovative actions to tackle inappropriate use of
antimicrobials and overcome barriers to innovation.
OECD Recommendation 4 states that both upstream and
downstream economic incentives should be combined and
should aim to de-link development incentives from sales,
and encourage the participation of small and medium-sized
enterprises (SMEs) in R&D efforts. A good package would
include establishing a global collaborative research platform, milestone prizes and grants, patent buyouts, and a
globally coordinated approach to clinical trials.
• The World Health Organization (WHO) has recently upscaled
effort on AMR and its Global Plan of Action on AMR9 was
adopted in 2015,10 after the issue had been referred to in
a number of previous World Health Assembly Resolutions.
The Resolution mandates WHO, inter alia:
“[...]
(2) to ensure that all relevant parts of the Organization, at
headquarters, regional and country levels, are actively
engaged and coordinated in promoting work on containing
antimicrobial resistance, including through the tracking of
resource flows for research and development on antimicrobial resistance in the new global health research and
development observatory;
[...]
(5) to develop and implement, in consultation with Member
States and relevant partners, an integrated global program for surveillance of antimicrobial resistance across
all sectors, in line with the global action plan;

3

The Council of the European Union, A strategy against the microbial threat, Resolution no. 1999/C and 195/01.

4

The Council of the European Union, The prudent use of antimicrobial agents in human medicine, Resolution no. 2002/77/EC.

5

2009 EU-US Summit Declaration (p. 3), November 3, 2009.

6

Transatlantic Taskforce on Antimicrobial Resistance; available at www.cdc.gov/drugresistance/tatfar

7

Transatlantic Taskforce on Antimicrobial Resistance: Progress Report, May 2014; available at http://www.cdc.gov/drugresistance/pdf/tatfarprogress_report_2014.pdf

8

Michele Cecchini, Julia Langer and Luke Slawomirski, Antimicrobial Resistance in G7 Countries and Beyond: Economic Issues, Policies and Options
for Action, OECD Report, 2015.

9

Global Health Action Plan on Antimicrobial Resistance, WHO Report, Geneva, Switzerland, 2015; available at http://apps.who.int/iris/
bitstream/10665/193736/1/9789241509763_eng.pdf?ua=1

10 Sixty-eighth World Health Assembly, agenda item 15.1, Global Action Plan on Antimicrobial Resistance, A68/A/CONF./1 Rev.1, May 25, 2015;
available at http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_ACONF1Rev1-en.pdf?ua=1
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(6) to establish a network of WHO Collaborating Centres to
support surveillance of antimicrobial resistance and quality assessment in each WHO region;
(7) to develop, in consultation with Member States and relevant
partners, options for establishing a global development
and stewardship framework to support the development,
control, distribution and appropriate use of new antimicrobial medicines, diagnostic tools, vaccines and other
interventions, while preserving existing antimicrobial medicines, and promoting affordable access to existing and
new antimicrobial medicines and diagnostic tools, taking
into account the needs of all countries, and in line with
the global action plan on antimicrobial resistance, and to
report to the sixty-ninth World Health Assembly;
[...]”

• There have been a number of papers that have reviewed
and critically assessed incentive strategies for discovery
and development of new antibiotics.15, 16, 17, 18
• One example of the use of prizes is the United Kingdom
(UK) Longitude Prize, which offers GBP 10 million to a
successful researcher.19
• A recent study by the Swiss Federal Office of Public Health
explores the national AMR strategies of a number of
European countries (Denmark, France, Germany, Norway,
Sweden, Switzerland and the UK) as well as South Africa
and the USA to add additional perspectives. The study
includes an assessment of the various approaches and
best practices.20

• In order to implement the suggestion of the Action Plan to
create new partnerships for the development and conservation of antibiotics, WHO with the Drugs for Neglected
Diseases initiative (DNDi) have jointly launched the Global
Antibiotic Research & Development Partnership, which is
discussed in greater detail below.
• The Uppsala Health Summit in June 2015 tackled the full
range of issues, including the need for access – not excess
– when it comes to the use of antibiotics, collaborative
innovation models, and global governance. They highlighted the crucial role of vaccines in preventing disease and
diagnostics in establishing what constitutes appropriate
use of antibiotics.11
• In October 2015, the G7 Health Ministers met to discuss
AMR and Ebola. Their Declaration12 fully supports the WHO
Action Plan and identifies the need to explore the setting-up
of a global antibiotics product development partnership,
mentioning the WHO/DNDi proposed initiative.
• In addition to the political focus, there are a vast number
of new publications covering the extent of the threat posed
by AMR/MDR and possible solutions to address the problems.13 The Lancet Infectious Disease Commission highlighted that, although the causes of AMR are complex, the
consequences affect everybody in the world.14

11 Uppsala Health Summit 2015: A World Without Antibiotics, 2015; available at http://www.uppsalahealthsummit.se/
our-summits/a-world-without-antibiotics-2015
12 Declaration of the G7 Health Ministers, October 8-9, 2015, Berlin; available at http://www.bmg.bund.de/fileadmin/dateien/Downloads/G/G7-Ges.
Minister_2015/G7_Health_Ministers_Declaration_AMR_and_EBOLA.pdf
13 AMR Control 2015, Overcoming Global Antimicrobial Resistance, The World Alliance Against Antibiotic Resistance (WAAR), 2015.
14 Antibiotic Resistance – The Need for Global Solutions, The Lancet Infectious Diseases Commission, 2013.
15 Renwick, M.J., D.M. Brogan and E. Mossialos, “A systematic review and critical assessment of incentive strategies for discovery and development of
novel antibiotics”, The Journal of Antibiotics, 2015.
16 “Approaches to simulating innovation for development of new antibiotic drugs”, KEI, 2013.
17 Strategic Research Agenda, Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), December 5, 2015.
18 Towards a New Global Business Model for Antibiotics – Delinking Revenues from Sales, The Royal Institute of International Affairs, Chatham
House, October 2015.
19 https://longitudeprize.org/challenge/antibiotics
20 Dr. Mathias Bernhard Bonk, Responses to the Antimicrobial Resistance Threat: A Comparative Study of Selected National Strategies and Policies,
Swiss Federal Office of Public Health (FOPH), Division of International Affairs, May 2015.
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3. Broad overview of current
market issues related to AMR/
MDR and trends in R&D for
new antibiotics covering both
private and public sectors
There is a lack of new antibacterial medicines and vaccines as the growth in
AMR/MDR has been accompanied by a sharp decline in development of new
treatments. Over the past three decades only two new classes of antibacterial
medicines have been discovered, compared to 11 in the previous 50 years. The
number of antibiotics becoming obsolete due to resistance significantly exceeds
the number of new, approved treatments.21
The two new classes of treatments relate to pulmonary multidrug-resistant tuberculosis (MDR-TB), where drug resistance has been on the rise. The first is Otsuka’s
delamanid, which was granted approval in 2014 by Japan, the Republic of Korea
and within the EU (to be used in combination with other anti-TB medicines). In
November 2014, WHO issued policy guidance on the use of delamanid, to assist
access in developing countries. The second was Janssen Pharmaceutical’s
bedaquiline, which was granted approval in Peru, the Philippines, the Republic of
Korea, the Russian Federation, South Africa and the USA. In 2015 the US Food
and Drug Administration (FDA) approved ceftolozane/tazobactam (Zerbaxa) by
Cubist (fully owned by MSD) and Allergan/AstraZeneca’s Avycaz, both for the
treatment of complicated urinary tract and intra-abdominal infections, as well as
bacterial pneumonia.
The introduction of antibiotics and immunization has been a key contributor to
the reduction of deaths from infectious diseases and has helped to make modern
medicine possible.
As of September 2016, an estimated 4022 new antibiotic medicines with the potential
to treat serious bacterial infections are in clinical development for the US market.
The success rate for clinical drug development is low, and currently only around
one in five candidates that enter human testing (phase 1 clinical trials) will be
approved for patients.
Most of the private sector development remains focused on existing classes of
antibiotics where the risk of failure is significantly lower.23 Table 1 shows the current R&D underway by International Federation of Pharmaceutical Manufacturers
and Associations (IFPMA) member companies (April 2015). To share the risk of
development, the US Biomedical Advanced Research and Development Authority
(BARDA) directly supports companies that develop new antibiotics through
its Broad Spectrum Antimicrobials Program. BARDA, for example, launched
a Portfolio Partnership with GlaxoSmithKline to support the development of a
number of new antibiotics.24

21 Michael S. Kinch, Denton Hoyer, et. al., Yale Center for Molecular Discovery, 2014.
22 Antibiotics Currently in Clinical Development, The Pew Centre, December 2015.
23 Cristina d’Urso de Souza Mendes et al., Pipeline of Known Chemical Classes of Antibiotics,
December 2013.
24 https://www.hhs.gov/sites/default/files/barda_antimicrobial_program.pdf
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Table 1:
Current research and development underway by IFPMA member companies,
April 2015
Company

Compound Name or identifier

Compound
Category

Spectrum:
Gram-positive,
Gram-negative,
or both

Current
development
phase

AZ/Actavis

CAZ-104 Ceftazidime/Avibactam

Small molecule

Gram-negative

Phase 3

CXL-104 Avibactam/Ceftaroline

Small molecule

Gram-negative

Phase 2

CAZ-104 Ceftazidime/Avibactam

Small molecule

Gram-negative

Phase 3

AZ

Bayer

GSK

CXL-104 Avibactam/Ceftaroline

Small molecule

Gram-negative

Phase 2

AZD5847

Small molecule

M. tuberculosis

Phase 2

AZD0914

Small molecule

Gram-negative

Phase 1

MEDI4893

Large molecule

Gram-positive

Phase 1

ATM-AVI (Avibactam/Astreonam)

Small molecule

Gram-negative

Phase 1

MEDI3902

Large molecule

Gram-negative

Phase 1

Ciprofloxacin DPI (dry powder for inhalation)

Small molecule

Gram-negative

Phase 3

Amikacin Inhale

Small molecule

Gram-negative

Phase 3

Tedizolid

Small molecule

Gram-positive

Phase 3

Streptococcus pneumoniae

Vaccine

Gram-positive

Phase 2

GSK2140944

Small molecule

Gram-positive

Phase 2

GSK/Aeras

Tuberculosis

Vaccine

M. tuberculosis

Phase 2

Janssen

ExPEC

Vaccine

E. Coli

Phase 1

Merck & Co / MSD Imipenem/MK-7655

Small molecule

Gram-negative

Phase 2

MK-3415/MK-6072

Large molecule

C. difficile

Phase 3

V114 – Pneumococcal Conjugate

Vaccine

Gram-positive

Phase 2

Acellular pertussis booster

Vaccine

Gram-negative

Phase 1

Acellular pertussis combos

Vaccine

Gram-negative

Preclinical

MenABCWY

Vaccine

Gram-negative

Phase 2

Staphylococcus aureus

Vaccine

Gram-positive

Phase 1

Typhoid

Vaccine

Gram-negative

Phase 2

Group B streptococcus (GBS) conjugate

Vaccine

Gram-positive

Phase 2

PF-06425090

Vaccine

C. difficile

Phase 1

PF-06290510

Vaccine

Staphylococcus aureus Phase 2

RG7929

Large molecule

Gram-negative

RG6080

Small molecule

Diazabicyclooctane
Phase 1
beta-lactamase inhibitor
(BLI)

ACAM-Cdiff

Vaccine

C.difficile

Phase 3

Streptococcus pneumoniae

Vaccine

S. pneumoniae

Phase 1

Tuberculosis recombinant subunit

Vaccine

M. tuberculosis

Phase 2

Delamanid

Small molecule

M. tuberculosis

Phase 3

Delamanid (paediatric)

Small molecule

M. tuberculosis

Phase 2

Novartis

Pfizer

Roche

Sanofi

Otsuka

Source: Rethinking the Way We Fight Bacteria, IFPMA, 2015. Supplied courtesy of IFPMA.
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Phase 2

It is important to note that a significant repository of potential antibiotics is undoubtedly present in (currently largely untapped) biodiversity. As the tools of, and sophistication of, biotechnology advance, the potential for efficient, rapid and successful
bioprospecting of such antibiotic candidates has increased.25 The recent case
wherein “48 novel potential cationic antimicrobial peptides” were identified in the
plasma of Varanus komodoensis (Komodo dragon), indigenous to Indonesia, is
exemplary: “The antimicrobial effectiveness of eight… peptides was evaluated
against Pseudomonas aeruginosa… and Staphylococcus aureus… with seven
peptides exhibiting antimicrobial activity against both microbes and one only
showing significant potency against P. aeruginosa.”26 Coherent, coordinated and
equitable management of these biological resources and the potentially valuable
IP that results from research and development will be crucial for sustainable conservation of, and widespread access to, subsequent new antibiotics.27
Around 100 pharmaceutical and diagnostics companies (including support from
major trade associations such as the IFPMA) declared their commitment to combating AMR on January 21, 2016, at the World Economic Forum (WEF) in Davos.28
They called on governments to work with them in developing new and alternate
market structures to provide more dependable and sustainable market models.
This includes new incentives for R&D, new mechanisms to ensure that the price
of antibiotics reflects value, and payment models that reduce the link between
profitability and volume of sales. The declaration also sets out the commitment
by the companies across three broad areas:
1. reducing the development of drug resistance
2. increasing investment in R&D that meets global public health needs
3. improving access to high-quality antibiotics for all.
Pharmaceutical companies have reinforced their commitment to the January
2016 Declaration by issuing a Roadmap to Combat Antimicrobial Resistance29
just ahead of the United Nations General Assembly on September 20, 2016, and
pledged to deliver by 2020 to reduce AMR.

25 McClory, Haley, and Stanley P. Kowalski, “Horses as sources of proprietary information:
commercialization, conservation, and compensation pursuant to the Convention on Biological
Diversity”, AgBioForum 17(2): 141-155, 2014.
26 Bishop, Barney M., Melanie L. Juba, Paul S. Russo, Megan Devine, Stephanie M. Barksdale,
Shaylyn Scott, Robert Settlage et al., “Discovery of novel antimicrobial peptides from Varanus
komodoensis (Komodo dragon) by large-scale analyses and de-novo-assisted sequencing using
electron-transfer dissociation mass spectrometry”, J Proteome Res. 16(4): 1470-1482, 2017.
27 Multiple United Nations agencies work on the issue of fair and equitable sharing of benefits for
the use of genetic resources. WIPO facilitates normative activities and provides capacity-building
on the relationship between IP and access to, and benefit-sharing in, genetic resources and
associated traditional knowledge; see www.wipo.int/tk/en/genetic
28 https://amr-review.org/industry-declaration.html
29 www.ifpma.org/wp-content/uploads/2016/09/AMR-Roadmap-Press-Release_FINAL.pdf,
https://accesstomedicineindex.org/best-and-innovative-practices/commitment-to-rd-for-amr
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4. Preliminary survey of
initiatives, partnerships
and consortia engaged
in the development of
antibiotics
4.1 The WHO/DNDi Global
Antibiotic Research & Development
Partnership (GARDP)
The Global Antibiotic Research & Development Partnership
was launched on May 24, 2016.30 The partnership aims to
promote antibiotic product development and pilot incentive
models that de-link the cost of R&D from volume-based
sales and contribute to the conservation of, and access to,
new antibiotic treatments. This provides an alternative to
the traditional market-driven pharmaceutical approach, by
focusing on products that the pharmaceutical industry will
likely not develop for lack of commercial incentive.
The partnership goes back to a call in the WHO Global Action
Plan on Antimicrobial Resistance (adopted in May 2015) for
the creation of new partnerships to foster the development
and conservation of antibiotics. To implement this part of the
Plan, WHO and the Drugs for Neglected Diseases initiative
(DNDi) are working in a new partnership that seeks to:
1. develop new antibiotic treatments addressing antimicrobial resistance
2. pilot and test alternative incentive models that promote
innovation and access
3. promote their responsible use for optimal conservation
4. ensure equitable access for all by making products affordable, subject to a global conservation agenda
5. guarantee new products that are suitable for resourcelimited settings.

4.2 The Innovative Medicines Initiative (IMI)
The Innovative Medicines Initiative is Europe’s largest public-private initiative aiming to speed up the development of
better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and
academic experts in order to boost pharmaceutical innovation
in Europe. One of its priorities is antimicrobial resistance.
IMI’s program New Drugs 4 Bad Bugs (ND4BB) focuses
on the scientific, regulatory and business challenges that
are hampering the development of new antibiotics. ND4BB
includes, inter alia, the creation of a pan-European network
of excellence of clinical investigation sites, basic research to
tackle, in particular, gram-negative bacteria, the development
of a specific drug discovery platform for antibiotics, and the
exploration of new economic models for antibiotic development
(DRIVE-AB).31 AMR is a growing problem worldwide, and
with few new drugs making it to the market there is an urgent
need for new medicines to treat resistant infections. Also the
Combatting Bacterial Resistance in Europe (COMBACTE)
project forms part of the ND4BB initiative and aims to pioneer
new ways of designing and implementing efficient clinical
trials for novel antibiotics.32

4.3 The EU Joint Program Initiative
on Antimicrobial Resistance
The EU Joint Program Initiative on Antimicrobial Resistance
has been set up to pool national research efforts to spend
public R&D resources more efficiently.

Joint programming is used in different areas to overcome the
fragmentation of national research programs, in particular
where challenges are global in nature. The development of
new preventative and therapeutic approaches is only one of
many areas that form part of the Joint Programming Initiative
on AMR. Research priorities are set out in the Strategic
Research Agenda, and that agenda is implemented through
launching joint calls for proposals to facilitate cross-border
research projects. The focus of the Initiative is basic research;
The Partnership is working closely with all stakeholders – it does not currently finance product development.
including pharmaceutical and biotechnology companies, other
product development partnerships, academia, civil society, 4.4 US Broad Spectrum
research organizations and health authorities – from coun- Antimicrobials Program
tries of all income levels to develop new antibiotic treatments
and to preserve them.
BARDA’s Broad Spectrum Antimicrobials (BSA) Program was
established in January 2010 and is focused on developing
novel antibacterial and antiviral drugs for the treatment or
prevention of disease caused by currently defined and future
biological threats.33 The program recognizes that new antimicrobials are needed immediately to address the increasingly
prevalent public health threat of antibiotic resistance, as well
as the likelihood that AMR will complicate standard treatment
of a wide array of infections. One of the main objectives is to
revitalize the antimicrobial pipeline by providing incentives for
30 https://www.dndi.org/diseases-projects/gardp/
31 Ciabuschiet, Årdal, Findlay et al., WP2: Creation and testing of new economic models; Incentives to stimulate antibiotic innovation:
The preliminary findings of DRIVE-AB; available at http://drive-ab.eu/wp-content/uploads/2016/06/WP2-Prereading-FINAL.pdf
32 https://www.combacte.com
33 https://www.medicalcountermeasures.gov/barda/cbrn/broad-spectrum-antimicrobials.aspx
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pharma and biotech companies to engage (or re-engage) The Review published its final report on May 19, 2016 and
in antimicrobial development (as mentioned in Section 2). proposed nine interventions ranging from a global awareness
Since that time around six companies have entered into col- campaign to improved sanitation and the development of
laborative partnerships with BARDA34 and they have invest- new diagnostics, medicines and vaccines.37 Two particular
ed hundreds of millions of dollars in supporting late-stage interventions worthy of note are the creation of a global innodevelopment, including through partnering with biotech and vation fund for early-stage and non-commercial R&D, and
pharmaceutical companies.
better incentives to promote investment for new drugs and
improving existing ones. Both of these will be considered in
It is hoped that this strategy will ensure that novel antimicro- more detail later in this paper.
bials progress through the development pipeline to approval,
so that novel antimicrobials will be added to the arsenal of As a result of the review, the UK launched The AMR Centre,
possible treatments available. One recent announcement which forms a key part of the UK’s response to AMR. The
was for a single treatment for multiple common infections AMR Centre is a joint public-private initiative to support/
that had entered the last stages of development.35
accelerate the development of new antibiotics and diagnostics through a fully integrated development capability, offering
4.5 The Combating Antibiotic
translational R&D from pre-clinical hits through to clinical
Resistant Bacteria Biopharmaceutical
proof of concept.38

Accelerator (CARB-X)

A further initiative was launched in July 2016 called CARB-X
(Combating Antibiotic Resistant Bacteria Biopharmaceutical
Accelerator). BARDA claims that it is possibly the largest
public-private partnership in the world dedicated to preclinical
antibiotic development. It involves seven partners in the UK
and USA, and is backed with half a billion US dollars in funding.
CARB-X partners are working together to set up a diverse
portfolio with more than 20 high-quality antibacterial products.36

4.6 The UK independent Review
on Antimicrobial Resistance
The UK independent Review on Antimicrobial Resistance,
chaired by Jim O’Neill, was commissioned by the UK Prime
Minister to analyze and propose concrete actions to tackle
the global problems of antimicrobial resistance. The Review
had to assess the extent to which market failure is responsible
for the lack of investment in R&D of new antimicrobials and
identify short-, medium-, and long-term interventions that
could be undertaken by governments and other funders to
stimulate investment in new antimicrobials for human use.
In 2015, the Review published initial proposals to kick-start
antibiotic drug discovery efforts at a global level. The proposals include channeling new funds into early-stage research,
as well as creating a fund for product development to buy
out major new breakthroughs. The latter could ensure a
predictable and viable market for new antibiotics, providing
an incentive for companies to invest.

4.7 Additional remarks
The above list is not intended to be exhaustive and there may
be other valuable initiatives that have not been mentioned.
However, it is noted that the majority of initiatives involved
developed countries, although there has been some political will to support focus on AMR from the G20 countries.39
Although the enhanced focus is warmly welcomed by many,
there is an increased need to ensure effective alignment and/
or coordination within the AMR landscape in order to fill the
necessary gaps and avoid duplication. There also needs to be
an assessment of the contribution and value of each initiative
so that successful platforms can be enhanced, while platforms
that fail to meet expectations can be re-tasked or refocused.
WHO has proposed options for establishing a global development and stewardship framework.40 However, countries
will need to be open to sharing information and allowing
their national programs to be shaped and influenced for
global success41 rather than national interests, if the shared
goal is to be realized. The Political Declaration42 of the HighLevel Meeting of the United Nations General Assembly on
Antimicrobial Resistance on September 21, 2016, will help to
achieve this by summoning and maintaining strong national,
regional and international political commitment in addressing
antimicrobial resistance comprehensively and multi-sectorally,
and to increase and improve awareness.43

34 Ibid. 24.
35 http://wayback.archive-it.org/3926/20170127233945/https://www.hhs.gov/about/news/2016/04/20/hhs-sponsors-new-broad-spectrum-antibioticdevelopment.html
36 www.carb-x.org
37 Tackling Drug-Resistant Infections Globally: Final Report and Recommendations, The UK Review on AMR, May 2016; available at https://amr-review.org
38 http://amrcentre.com, launched May 2016.
39 G20 Agriculture Ministers Meeting Communiqué, June 3, 2016; available at http://www.g20chn.org/English/Documents/Current/201606/
t20160608_2301.html
40 WHO Global action plan on antimicrobial resistance, Options for establishing a global development and stewardship framework to support the
development, control, distribution and appropriate use of new antimicrobial medicines, diagnostic tools, vaccines and other interventions, A69/24
Add.1., May 13, 2016.
41 Jinks et al., “A time for action: antimicrobial resistance needs global response”, WHO Bulletin, 2016.
42 www.un.org/pga/71/wp-content/uploads/sites/40/2016/09/DGACM_GAEAD_ESCAB-AMR-Draft-Political-Declaration-1616108E.pdf
43 www.un.org/pga/70/events/high-level-meeting-on-antimicrobial-resistance
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5. Global experience
A review of the literature revealed significant differences in the way countries use antibiotics. For
example, in Europe, the Scandinavian countries use relatively few antibiotics, and consequently have
very low levels of resistance. On the contrary, countries like Greece, Italy and a number of Eastern
European countries are relatively heavy users and hence display pronounced levels of antibiotic resistance. Many other regions and countries, like India, China and the Americas, are heavy users, and
also use antibiotics as animal growth promoters. Hence the same huge differences are seen in animal
production-related use as some countries are adding antibiotics to animal feed as a matter of course.
Evidence shows that in low-income and middle-income countries (LMICs), antibiotic use is increasing
with rising incomes, high rates of hospitalization, and high prevalence of hospital infections.44 However,
where there are weak health systems, the effect of AMR on health and economics is largely underestimated and incompletely understood.45 It largely follows that effective access is hindered where
there are weak health systems. At least two-thirds of childhood mortality is related to infections, and
children are therefore probably more vulnerable than adolescents and adults.46
The global market value of veterinary drugs increased from USD 8.7 billion in 1992 to USD 20.1 billion
in 2010, and in 2018 is anticipated to reach USD 43 billion.47, 48, 49 Overuse of antibiotics in animals
remains a key problem. For example, China is one of the world’s highest users of the antibiotic colistin
in agriculture and it is suggested that this heavy use has resulted in resistance.50 Resistance travels
fast and hence a Chinese problem fast becomes a global one. Therefore no country can successfully
tackle AMR by acting in isolation.51
Other problems include overprescribing or unregulated use of antibiotics. In China, for instance, hospitals and clinics receive financial incentives for prescribing, and antibiotics are overused as a result.52
Some countries allow pharmacies to sell antibiotics without prescription and people buy them even
for diseases that antibiotics cannot treat, such as malaria.53
There are significant similarities within all countries as there is a need for an effective health system.
Ensuring access and appropriate use depends on multiple factors operating within a well-functioning
and well-managed national healthcare system:
• rational selection and use
• affordable prices
• sustained financing
• reliable health supply systems
• robust regulation and enforcement systems.54

44 Ibid. 13.
45 Antibiotic Resistance – The Need for Global Solutions, The Lancet Infectious Diseases Commission, 2013.
46 Liu et al., for the Child Health Epidemiology Reference Group of WHO and UNICEF, “Global, regional, and national causes
of child mortality: an updated systematic analysis for 2010 with time trends since 2000”, Lancet 2012; 379: 2151–61.
47 Global Industry Analysts, “Animal health market to hit $43 billion in five years”, Western Farm Press, August 13, 2012;
available at http://westernfarmpress.com/management/animal-health-market-hit-43-billion-five-years
48 Van Boeckel, T.P., C. Brower, M. Gilbert, et al., “Global trends in antimicrobial use in food animals”, Proc Natl Acad Sci
USA, 2015; 112: 5649–5654.
49 QYResearch Medical Research Centre, The Global Polymyxin Industry Report, 2015; available at www.qyresearch.com
50 Yi-Yun Liu, Yang Wang, et al., “Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and
human beings in China: a microbiological and molecular biological study”, Lancet 2016 Volume 16: 161–168.
51 Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations, The UK Review on AMR, December
2014; available at https://amr-review.org
52 Reardon, “Antibiotic resistance sweeping developing world – Bacteria are increasingly dodging extermination as drug
availability outpaces regulation”, Nature, May 6, 2014.
53 Ibid. 50.
54 Eveline Wesangula, Fostering access to, and appropriate use of, antibiotics – a balancing act, WHO, WIPO, WTO
Technical Symposium on Antimicrobial Resistance: How to Foster Innovation, Access to, and Appropriate Use of
Antibiotics, October 25, 2016; available at www.wipo.int/meetings/en/2016/wipo_wto_who_technical_symposium.html
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GARDP held a regional workshop in Cape Town, South Africa, in September 2016.55 Forty-five participants from 11 African countries participated in the meeting.
The following needs and challenges were noted:
• Many African countries have weak health systems.
• Africa has a high burden of disease, e.g. TB and malaria, and malnutrition is a major problem.
• There is a scarcity of data on AMR.
• Policies and regulations that make sense and ensure stewardship and access at national level are
needed.
• There is a need to undertake R&D to address ESKAPE56 pathogens, as well as the resistant sexually
transmitted infections and resistant infections along with the emerging threat from Candida Auris.
The priorities that were identified included:
• rapid point-of-care tests to distinguish bacterial from viral infections, as well as pathogen-specific tests
• diagnostics support for stewardship
• stewardship cannot be seen as a national effort – it must be regionally harmonized
• establishment of an African-driven and coordinated AMR clinical trial network that should capitalize
on several existing networks and create centres of excellence for trials
• dissemination of national guidelines to medical practitioners and hospitals would help support standardization of care.
In Kenya, it was identified that the best immediate approaches for appropriate use include:
• increased use of vaccines that reduce disease and therefore antibiotic demand
• improved infection control, including procedures (e.g. hand hygiene, checklists) and information
guidelines, particularly in hospitals
• education and public awareness campaigns for providers and consumers.
Three additional important approaches, which are not immediately implementable, are:
• increased use of improved diagnostics, to better target antibiotic use
• resolution of supply-chain constraints and failures
• economic incentives to encourage better use of antibiotics.57
Poor countries often suffer from lack of regulations for antibiotics, leading to access to substandard
or falsified antibiotics. Substandard antibiotics often have a lower dosage of the active ingredient that
results in increased resistance.58 It is clear that policies for appropriate supervision and control by regulatory agencies are needed to prevent the supply of expired, substandard and counterfeit medicines.
Evidence suggests that when antibiotics are available the issues are the same for all countries. Overuse
leads to greater levels of resistance and hence effective antibiotic stewardship is crucial. However,
sustainable access to effective antibiotics, both existing and new, remains a key challenge.

55 Meeting report Antimicrobial Resistance (AMR) Research and Innovation: Addressing Africa’s Regional Priorities, Cape
Town Lodge Hotel, Cape Town, South Africa, September 1, 2016.
56 ESKAPE stands for the following pathogens: enterococcus faecium, staphylococcus aureus, klebsiella pneumoniae,
acinetobacter baumannii, pseudomonas aeruginosa and enterobacter. See: Helen W. Boucher, George H. Talbot, John S.
Bradley, John E. Edwards, David Gilbert, Louis B. Rice, Michael Scheld, Brad Spellberg, John Bartlett, “Bad Bugs, No
Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America”, Clin Infect Dis (2009) 48 (1): 1-12., DOI:
https://doi.org/10.1086/595011
57 Samuel Kariuki, Situational Analysis and Recommendations: Antibiotic Use and Resistance in Kenya, August 2011.
58 Michael A. Kohanski, Mark A. DePristo, James J. Collins “Sublethal antibiotic treatment leads to multidrug resistance via
radical-induced mutagenesis”, Molecular Cell, Volume 37, Issue 3, 311-320, February 12, 2010.
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6. Intellectual property
related issues
This section looks at the role of IP – both in terms of incentivizing R&D and preventing possible generic companies from
entering the market.
IP is a part of the enabling environment for innovation and
as such a policy tool to incentivize or enable innovation by
providing a fixed period of exclusivity for full public disclosure. However, the patent system can only contribute as an
effective incentive mechanism if there is, or will be, sufficient
market drivers. In the normal business model of medicine
development, the innovator calculates a price based on a
number of factors - including market dynamics, cost of R&D,
etc. Once a patent expires, providing regulatory approval
has been obtained, generic companies are able to sell the
medicine and compete based on sales volume.
There are a number of problems with this model when
addressing AMR/MDR. Firstly, pharmaceutical companies
are reluctant to invest in antibiotic R&D because the returns
are significantly lower than for other areas, leading to many
companies exiting the market. There are unique problems
when developing the next generation of antibiotics:
• Limited use. New antibiotics were often reserved as drugs
of “last resort” and used “sparingly” for “short” courses of
treatment. In contrast, treatments for mental illnesses or
cancer may last for several weeks, months or even years,
providing greater opportunity for those treatments to deliver
a return on investment.
• Low price. Existing antibiotics are very cheap and are
generally only used for a short period of time.
• Short lifespan. Antibiotics can have a short working lifespan, as resistance may develop to compounds in a relatively
short period of time, sometimes at the clinical trial stage.
• Clinical trials. Conducting clinical trials of antimicrobials
is difficult because it is often not clear which pathogen was
affecting a patient, diagnosis time can be lengthy and highly selective patient populations are required. If the value
of a new antibiotic can only be demonstrated on patients
who display infection resistance then clinical development
becomes prohibitively lengthy and expensive until resistance becomes widespread.

Despite the clear value of antibiotics for society, the incentives to develop them are notably small. This led to less than
5 percent of venture capital investment in pharmaceutical R&D
between 2003 and 2013 being allocated to AMR.59 Creating
a vibrant and sustainable pipeline remains a primary objective and there are numerous initiatives underway to develop
incentives to stimulate antibiotic innovation. The recently
launched DRIVE-AB initiative has already published a shortlist of push and pull models/mechanisms to incentivize R&D.60
Generally, innovators and generics are commercially incentivized to sell high volumes of product. This cannot work in
the case of AMR/MDR as the goal is to provide access to
only those patients who absolutely need the state-of-the-art
treatment.61 Low sales generally lead to an unsustainable
business model, but high levels of sales would result in
overconsumption and contribute to high levels of resistance.
Hence, simply increasing developer return on investment
(ROI) does not address the problem directly.
Therefore, alternative mechanisms are required to help
de-risk62 or de-link63 companies’ initial investment.
Numerous experts have proposed antibiotic business models that reinforce conservation efforts by completely severing a developer’s ROI from sales volume and price. This
concept is known as “de-linkage” and is beneficial for three
key reasons. Firstly, it provides developers with a concrete
ROI that is extraneous to the market. Secondly, it removes
the motivation for developers to overmarket their antibiotic.
Thirdly, it facilitates access to new antibiotics for those who
need them most.64 An additional possible benefit is that it
may encourage collaboration and coordination (avoiding
duplication) since incentives can be provided to consortia.
Other experts advocate the use of demand-side antibiotic
usage fees to internalize the negative externalities accompanying antibiotic use. This fee can then be used to finance other
incentive mechanisms such as milestone payments or end
prizes.65 For example, the Boston Consulting Group’s report
to the German Government recommended the creation of:
• a Global Research Fund – to support academics and SMEs
(starting budget of USD 200 million)
• a Global Development Fund – to support promising drug
candidates (annual budget of USD 200 million)
• a Global Launch Reward of USD 1 billion for a successful
product that meets certain criteria.66

59 Renwick, M.J., V. Simpkin and E. Mossialos, International and European Initiatives Targeting Innovation in Antibiotic Drug Discovery and
Development, The Need for a One Health – One Europe – One World Framework, Report for the 2016 Dutch Presidency of the European Union.
60 Ibid. 31.
61 Securing New Drugs for Future Generations: The Pipeline of Antibiotics, The Review on Antimicrobial Resistance, May 2015.
62 Rethinking the Way We Fight Bacteria, IFPMA, 2015.
63 Antimicrobial Resistance in G7 Countries and Beyond, OECD, 2015.
64 Renwick, M.J., V. Simpkinand E. Mossialos, “A critical assessment of incentive strategies for development of novel antibiotics”, LSE Health, London
School of Economics and Political Science, October 31, 2014.
65 Ibid. 15.
66 London Boston Consulting Group, Breaking through the Wall – A Call for Concerted Action on Antibiotics Research and Development,
commissioned by the German Federal Ministry of Health, February 2017.
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The UK Review on AMR proposed a system of market entry
rewards (MERs) of around USD 1 billion per drug for effective
treatments, whether they are based on new or old drugs that
work against resistant pathogens in areas of most urgent
need.67 This would be funded by an “antibiotic investment
charge”, which would be imposed widely on the pharmaceutical sector and applied on a “pay or play” basis, meaning
companies could either pay the charge or invest in R&D that
is deemed useful for AMR. However, some worry that this is
not the best method of encouraging R&D. Many companies
are simply not geared up to commence AMR R&D and hence
may regard this as simply another tax.68 Irrespective of how
MERs would be financed, it is important to work out how IP
associated with such a prize mechanism could be handled.
For example, would IP rights simply be transferred on receipt
of the reward or would there be a sliding scale with a limited
sub-license at the other end of the compendium? The most
suitable approach could be guided by a number of factors
including complexity and cost of manufacture, volume required,
securing of regulatory approval in target countries, etc.

Figure 2:
Patent filings by public and private
organizations, January 2007-May 2017

Public
32%
Private
68%

Source: Stanley Kowalski, patent search on May 12, 2017 in Derwent
Innovation (formerly Thomson Innovation).

In the case of antibiotics, there is a need for restricted use,
hence limited market opportunity. One proposal has been to
create the possibility of transferrable IP rights.69 This would
mean that a developer of a new and high-value antibiotic
would be rewarded with the opportunity to extend patent term
on another medicine to enable recuperation of R&D spent,
given that the market for any new antibiotic will likely remain
very small. This idea has received a negative response from
the NGO community, which feels that the ultimate price of
an extended “blockbuster”70 medicine would outweigh the
cost of antibiotic R&D.71

Public research
organizations
8
Biotech
companies
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Other
2

Pharmaceutical
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A further idea would be to give antibiotic developers exchangeable “vouchers” as an incentive. While one type of voucher
relates to a transferrable IP right, the other type relates to a
priority review of any medicine waiting approval by a regulator.
This would mean that a medicine could receive accelerated
review with a view to rapid placement in the market. The
recipient developer could either use it for one of their own
medicines or sell it to another developer. Although this would
clearly provide an incentive, its value would diminish if there
were a significant increase in voucher availability.72 Such an
approach might be considered for the creation of new and
effective diagnostic tests. As noted above, such a test would
be highly valuable in ensuring appropriate antibiotics use and
monitoring/surveillance of AMR/MDR.

67 Ibid. 37.
68 Schoonveld, The UK’s Pay-or-Play Solution: A Horribly Flawed Idea, May 20, 2016.
69 Ibid. 8.
70 A blockbuster medicine is one that generates annual sales of at least USD 1 billion for the company that creates it.
71 Approaches to Simulating Innovation for Development of New Antibiotic Drugs, KEI, 2013; available at www.who.int/phi/implementation/annex_
antibiotic_research_development.pdf?ua=1
72 Outterson, K., and A. McDonnell, “Funding antibiotic innovation with vouchers: Recommendations on how to strengthen a flawed incentive policy”,
Health Affairs, 2016, 35, 5.
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7. High-level patent trends
over the past 10 years
Patent trends for AMR over the past 10 years were analyzed to determine which entities have been
most active. Table 2 shows the list of the top 25 applicants/assignees of patent documents between
2007 and 2017. Of the identified documents, 68 percent pertain to filings from private entities and
28 percent to public institutions (Figure 2). Among the putative patent owners are 11 pharmaceutical
companies, four biotechnology companies, eight public sector research organizations and two other
entities (Figure 3).

Table 2:
Antibiotic patent data with putative owners of intellectual property
rights by the world’s top 25 pharmaceutical companies and public
research institutions in the area of antibiotics, January 2007-May 2017
Twenty five top Applicants/Assignees

Patent Documents
(applications, grants, etc.)

Country

Genentech Inc.

324

US

Merck Sharp & Dohme (incorporating Schering Corp.)

229

US

Vertex Pharma

222

US

Private sector entities

Immunomedics Inc.

204

US

Abbott Laboratories

138

US

GSK (incorporating Smithkline Beecham Corp.)

132

UK

Novartis AG

115

CH

Idera Pharmaceuticals INC.

112

US

Celgene Corp.

111

US

Foamix Ltd.

109

US

Amgen Inc.

106

US

Medtronic Vascular Inc.

106

US

Abbvie Inc.

96

US

The General Hospital Corporation

93

US

Paratek Pharmaceuticals Inc.

90

US

Pfizer (incorporating Wyeth Corp.)

75

US

Hoffmann-La Roche

70

CH

University of California

246

US

Public sector entities
University of Texas

149

US

Tufts College

124

US

Centre national de la recherche scientifique

117

FR

Johns Hopkins University

102

US

Massachusetts Institute of Technology

93

US

Boston University

75

US

Harvard College

74

US

Source: Stanley Kowalski, patent search on May 12, 2017 in Derwent Innovation (formerly Thomson Innovation).
Search Parameters: combined US granted, US applications, EPO granted, EPO applications and Patent Cooperation Treaty
(PCT); search terms: IPC = A61K and Claim = Antibio! and Priority Date: 2007 to 2017. The IPC A61K appears to prevail on the
most relevant results (oral antibiotics patents) that were found initially via a simple keyword search approach. A subsequent
search sought to refine the results, i.e., via a hybrid keyword (limited to claim) combined with (“and”) the identified mostprevalent IPC. This is a simple Boolean strategy using set theory to delineate data (restricted keyword plus IPC) and then
identify a combined subset which has a higher likelihood of having relevant results.

14

Figure 3:
Patent filings by type of organization, January 2007-May 2017
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Source: Stanley Kowalski, patent search on May 12, 2017 in Derwent Innovation (formerly Thomson Innovation).

The data show that patenting activity of the last 10 years is relatively strong. However, this does not
correlate to the number of new antibiotics produced over the same period and patenting tends to focus
on existing classes of antibiotics, with more patent families directed towards the penicillin antibiotics
than any other known class. This is an interesting trend that shows that they still have a significant role
in tackling bacterial infections despite widespread resistance and their repeated use. This increment
developed within such a well-known existing class shows that there remains a strong possibility of
new therapeutic application.
The US has the highest number of patent applications since 2004 – almost twice as many as Europe
(via the European Patent Office (EPO)) and China (Figure 4). The penicillin class of antibiotics attracts
the highest number of patent applications (families) (Figure 5) and, although the pioneering class was
discovered almost 90 years ago, it remains relevant for treatment today.

Figure 4:
Total patent applications relating to antibiotic
research in top jurisdictions, 2004–2015
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Source: Medicines for rare diseases, vaccines and antibiotics, Marks & Clerk, Life Sciences Report, 2015.

ent applications

Although some large companies have abandoned research in AMR/MDR and other communicable
disease areas, a number of large and small companies are active in this field. The model is that they
undertake the research and early development but then license the candidate compound(s) to larger companies, which then undertake the risk and expense of completing the medicine development
process. For example, Iterum was set-up in March 2016 with an antibiotic licensed from an unnamed
pharmaceutical
company and joins a steadily growing group of biotechnology companies like Spero
3,500
and Cidara, which have been pushing ahead in the clinic with anti-infectives designed to meet the AMR
3,000
threat. Table 3 is a non-exhaustive list of licensing agreements over the past seven years.
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Figure 5:
Families of patent applications relating to research into specific known
classes of antibiotics, 2004–2015
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Source: Medicines for rare diseases, vaccines and antibiotics, Marks & Clerk, Life Sciences Report, 2015.

Table 3:
Current licensing agreements
Date

Licensor

Licensee

Details

Jan 2014

AstraZeneca
UK

FOB Synthesis

License covers combinations of the two companies’ experimental
medicines. AZ plans to test its own beta lactmase inhibitor alongside
the smaller company’s carbapenem medicines

Sept 2015

AstraZeneca
UK

US Dept. of Health Collaboration. Public-private partnership. Combining antibiotics to
& Human
tackle multi-drug resistant bacterial infections

May 2009

Aurobindo Pharma,
India

Pfizer

Licence includes antibiotics

May 2009

Claris LifeSciences,
India

Pfizer

Licence includes anti-infectives

March 2014

Discuva
UK

Roche

Worldwide collaboration and license agreement for the discovery
and development of new antibiotics to treat life-threatening infections
caused by multi-drug resistant Gram-negative bacteria using Discuva’s
proprietary SATIN technology platform

Jan 2015

Fedora Pharmaceuticals
Canada
With Meiji Seika

Roche

Worldwide license outside Japan for OP0595, a beta-lactamase
inhibitor in phase I clinical development for multidrug resistant bacterial
infections

March 2015

Harvard’s Office of
Macrolide
Technology Development Pharmaceuticals

License provides exclusive rights to develop novel macrolide antibiotics

Oct 2015

Harvard’s Office of
Opsonix
Technology Development

Exclusive license to develop a recombinant human protein derived from
mannose binding lectin to treat blood-born diseases, such as sepsis

April 2011

Janssen Pharmaceuticals Furiex
Pharmaceuticals

Acquired full licensing rights to develop broad-spectrum
fluoroquinolone antibiotic

Jan 2015

Meiji Seika
Japan
With Fedora
Pharmaceuticals

Roche

Worldwide license outside Japan for OP0595, a beta-lactamase
inhibitor in phase I clinical development for multidrug resistant bacterial
infections

Feb 2011

Optimer
USA

Astellas
Japan

License for fidaxomicin, which is a novel antibiotic used to treat
C. difficile

2014

Phylogica / Genentech

Roche

Research and licensing agreement, access to drug discovery platforms
for novel antibiotics

April 2014

Spero
USA

Roche

Partnership option to acquire a drug candidate from start-up Spero

July 2014

Trius Therapeutics

Bayer

Licensing of torezoid phosphate, a phase 3 antibiotic

Source: JS Consulting research, 2016.
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8. Opportunities for innovation
and intellectual property
systems
A suggested area of particular interest is the exploration of different business models.73 For example, ideas include the creation of a global antibiotics public-private
partnership; a global antibiotics fund, which could pool all existing funds under one
umbrella; a global procurement and distribution entity;74 and a global governance
system to ensure effective stewardship and rationale use.75
There are three possible non-exclusive options for the creation of the next generation of antibiotics (including AMR-associated vaccines and diagnostics):
1. private sector-driven R&D through the creation of new push and pull mechanisms
2. public-private partnerships where risks and rewards are shared and resources
are pooled
3. public funding where R&D priorities and associated implementation is agreed
at international/regional/national levels.
All the above options may work in developing new treatments for AMR/MDR.
However, whichever option or combination of options is used, it is crucial that
there is an effective international system of governance that facilitates rational
use at a national level, otherwise high levels of resistance are likely to continue.
Under option 1, there is a crucial need to develop a pool of incentives and information resources for antibiotic development. It is worth investing in the detailed
exploration of IP-linked incentive mechanisms that would clearly highlight the
benefits and considerations of each approach. The role of new and effective
vaccines and diagnostics will be important in preventing disease and ensuring
that the right treatment options are identified. Following on from the industry
declaration and roadmap,76 a further policy position was launched at the World
Economic Forum (WEF) in 2017 concerning the development of sustainable models to overcome the challenging economics of antimicrobial R&D. A key focus is
on pull incentives covering:
• market entry rewards
• insurance license models
• IP mechanisms.77
The B20 Health Initiative also included recommendations on AMR but went
broader than economic incentives and included reference to supporting GARDP,
harmonizing regulatory environments, development of guidelines for appropriate
use and advanced capacity building.78 The G20 Leaders’ Declaration supported
this approach by calling for the creation of a new international R&D Collaboration
Hub – to maximize the impact of existing and new antimicrobial basic and clinical
research initiatives, and to further examine practical market incentive options.79
73 Changes in the innovation landscape and new business models in medical innovation were
also discussed at the WHO, WIPO, WTO joined technical symposium on Medical Innovation
– Changing Business Models on July 5, 2013; see Wai, T. and P. Stevens, 2014, The Changing
Landscape of Medical Innovation: How Have Business Models Responded?, Global Challenges
Brief, WIPO: Geneva; available at www.wipo.int/meetings/en/2013/who_wipo_ip_med_ge_13
74 Securing New Drugs for Future Generations: The Pipeline of Antibiotics, The Review on
Antimicrobial Resistance, May 2015.
75 Business Model Options for Antibiotics, The Royal Institute of International Affairs (Chatham
House) and the Big Innovation Centre, February 2015.
76 Ibid. 28 and 29.
77 Sustainable models to overcome the challenging economics of antimicrobial R&D, IFPMA Policy
Position, January 18, 2017.
78 B20 Health Initiative, Stepping Up Global Health: Towards Resilient, Responsible and
Responsive Health Systems, May 18, 2017.
79 G20 Leaders’ Declaration, Shaping an interconnected world, Hamburg, July 7-8, 2017; available
at https://www.g20.org/gipfeldokumente/G20-leaders-declaration.pdf
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WIPO Re:Search80 is a consortium of public and private partners that aims to
accelerate the discovery and product development of medicines, vaccines, and
diagnostics to create new solutions for people affected by neglected tropical
diseases, malaria and tuberculosis by making IP and know-how available to the
global health research community. A Partnership Hub managed by BIO Ventures
for Global Health (BVGH) connects partners and brokers research collaborations.
WIPO Re:Search provides a mechanism which illustrates how IP issues can be
successfully handled to support developing and maintaining research partnerships.
WIPO Re:Search collaborations are based on Guiding Principles that establish
essential parts of the prospective license agreement, thereby considerably reducing the effort and costs of negotiating the license agreement.
WIPO Re:Search might serve as a case study that provides the experience of
partnering and connecting antibiotic researchers and developers and supporting
partnership building in the area of neglected tropical diseases, malaria and TB.
The role of the WIPO Re:Search Partnership Hub could be a model for AMR/MDR
research to proactively identify and facilitate collaborations that connect industry to
academic and other non-profit researchers. Such a model could be the principal
source of information on antibiotic research and development around the world,
so that potential partners could explore collaboration on existing projects or identify possible gaps. The experiences gained could serve GARDP, which seeks to
fill R&D gaps, particularly where a commercial incentive is insufficient. A WIPO
Re:Search-inspired platform might be used where candidate compounds might be
identified and shared in order to maximize collective input from potential partners.
The UK Review on AMR has proposed a global innovation fund but noted that
a number of existing funding mechanisms exist.81 Such funding has been made
available through various initiatives (as mentioned in Section 3) but there is a lack
of coordination and collaboration, and substantial gaps remain. A global fund
would ensure a holistic approach, but agreeing to common R&D priorities may
be challenging given the diverse burden of AMR/MDR around the world. How
to create government financing mechanisms has been discussed in WHO for
a number of years, with ideas ranging from taxing financial transactions or use
of commercial passenger airliners to commitments of percentages of GDP.82 A
number of mechanisms are referred to in Section 6. However, it is often the case
that government funders prefer to support initiatives within their own countries
and/or regions, where control is easier and other benefits, such as training of the
new generation of scientists and researchers, can be realized.83 The unique threat
posed by AMR/MDR provides a strong incentive to overcome these challenges
but it will take time and commitment to fully establish and operationalize. WHO,
as part of the implementation of the Global Action Plan, is currently starting a
project to identify global R&D needs. This is necessary to guide joint efforts such
as CARB-X or the WHO/DNDi GARDP initiative to address global R&D needs.

80 www.wiporesearch.org
81 Ibid. 37, page 49.
82 WHO, Report of the Consultative Expert Working Group on Research and Development:
Financing and Coordination: Research and Development to Meet Health Needs in Developing
Countries: Strengthening Global Financing and Coordination, April 2012.
83 Ben S. Bernanke, Promoting Research and Development: The Government’s Role, 2011.
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9. Access to new-generation
antibiotics and stewardship
Any stewardship framework needs to ensure access for patients who need treatments while preventing inappropriate use. An effective health system is essential
for both access and stewardship so that patients can be appropriately diagnosed,
treated (being made aware of the crucial importance of medicine adherence), and
cured. WHO has produced an options document that details key considerations
for the establishment of a global development and stewardship framework. This
includes the type of instrument that could be used, scope of medical products,
how to define and promote appropriate use, development of new treatments, tools
and vaccines and affordable access.84
The Medicines Patent Pool (MPP) has proven a successful innovation and access
model in the area of HIV/AIDS. Based on this success, the mandate of the pool
has expanded to include other communicable diseases such as Hepatitis C. The
value of this model is that a degree of antibiotic stewardship could readily be included as part of a licensing arrangement.85 The MPP, if deciding to enter the field of
antimicrobial medicines, could establish licensing agreements for AMR-related
vaccines and diagnostics. Prevention is always better than cure and effective
diagnosis is crucial to ensure appropriate use. Countries receiving new-generation antibiotics would first need to be assessed based on need. Applications for
new-generation antibiotics could be independently assessed by a panel of technical
experts, following a similar model to the Green Light Committee (GLC) Initiative,86
which assesses country applications for access to second-line anti-tuberculosis
medicines for the effective treatment of MDR-TB.
In addition to the above, patent-linked licensing arrangements could be used as
an enforcement mechanism to ensure compliance with stewardship requirements.
Failure to adhere to predetermined principles of stewardship undermines the
overall objective, and hence could lead to the restriction or prevention of future
supply to the entity that violates the terms of the agreement. It is crucial that an
effective sanction is in place, with the hope that implementation of such a sanction
will not be necessary.
The MPP has a similar mechanism with generic producers who are members of
the pool. Failure to utilize the license through manufacture and sufficient supply
of the associated product ultimately results in withdrawal of the license.87
There are opportunities for collaboration between different entities and initiatives
where expertise, best practice and networks could be combined to achieve shared
goals. For instance, platforms could be explored where various stakeholders could
come together for the development of combination treatments or other important
formulations.

84 Ibid. 41.
85 Kieny, M.P., Creating and Intergovernmental Consortium for New Antibiotics: A New
Development Model, 2015; Ibid. 18.
86 The Green Light Committee (GLC) Initiative, frequently asked questions document.
87 For example, Sublicense and Technology transfer Agreement between Bristol-Myres Squibb, the
Medicines Patent Pool Foundation and Cipla Ltd, December 14, 2015 (Article 12.3, page 16).
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10. Conclusion
Ultimately the most effective way to tackle AMR/MDR is to provide a global
framework88 that includes the full range of activities - including disease prevention,
awareness campaigns, improved sanitation, surveillance and monitoring - that are
able to be implemented effectively at a national level. But the development of new
diagnostics, medicines and vaccines remains a critical component that requires
new or adapted funding mechanisms and incentive systems.
As with many complex problems, there is no one-size-fits-all solution and both
public and private involvement, often in partnership, will be required to meet the
challenge. Maximizing the collective benefit from the significant range of experience,
expertise and resources available will require effective coordination, collaboration
and alignment at global and local levels.
The United Nations Ad-hoc Interagency Coordination Group on Antimicrobial
Resistance (AMR), established by the United Nations Secretary-General as mandated by UN Resolution 71/3 of October 5, 2016, began its work in May 2017.89 It
draws on expertise from all relevant stakeholders and is expected to report to the
General Assembly and make recommendations, including on options to improve
coordination. The Group can contribute to providing the necessary political support. Such support should include ministries of health, finance and agriculture,
given the potentially wide range of health, economic and social impacts involved.
This work can be complemented by formulating mechanisms that drive innovation
for results to incentivize success, while feeding expertise and experience into
stewardship and access efforts. Consideration should be given to how IP could
be used in any reward or prize system for AMR/MDR R&D – both in terms of
incentive and governance.
There are numerous frameworks that encourage cooperation and collaboration
between the public and private sector. Nevertheless, there is a need to connect
and synergize the identified best practice associated with these initiatives to the
challenges posed by AMR/MDR. WIPO Re:Search and the Medicines Patent Pool
are both strong examples of what can be achieved where normal market drivers
are limited or where complexities of collaboration exist. Policymakers should
consider how these mechanisms enable the sharing of experience, expertise and
know-how, reduce transactional costs, simplify licensing arrangements and terms
and enable the sharing of best practice. These findings and insights should be
extracted, refined and applied in the area of AMR/MDR so that the unique challenges of innovation, access and appropriate use can be effectively addressed.
AMR/MDR will impact all countries, but particularly those where health systems
need to be strengthened. Collaborative and urgent action should be seen as a
priority but finding a way to achieve this in practice will be the next important hurdle.

88 See, for example, ibid. 40 for a development and stewardship framework.
89 www.who.int/antimicrobial-resistance/interagency-coordination-group
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